JaxBio Technologies, a Netanya, Israel-based medical diagnostics company, received a €2.5M grant from the European Innovation Council (EIC) Accelerator.
This grant included the option for future blended financing, with a potential additional €9.1M from the EU and a matching €9.1M from other investors.
The company intends to use the funds to expand clinical programs and develop its diagnostics platform to create a blood test for making lung cancer detection and management simpler, quicker, and highly accurate.
Led by CEO and Founder Dr. Shahar Zirkin, JaxBio is developing a blood test for sensitive diagnosis of cancer and other diseases. Its liquid biopsy technology can detect thousands of cancer biomarkers in blood with high sensitivity and low cost to enhance diagnosis, monitoring, and therapy prediction. This lab process delivers next-day results, enabling quicker, better-informed decisions for healthcare providers and patients when time is critical.
FinSMEs
17/07/2024